DK159689A - Medikeret hudplejepraeparat, dets fremstilling og anvendelse - Google Patents

Medikeret hudplejepraeparat, dets fremstilling og anvendelse

Info

Publication number
DK159689A
DK159689A DK159689A DK159689A DK159689A DK 159689 A DK159689 A DK 159689A DK 159689 A DK159689 A DK 159689A DK 159689 A DK159689 A DK 159689A DK 159689 A DK159689 A DK 159689A
Authority
DK
Denmark
Prior art keywords
floor covering
earthing type
earthing
type
floor
Prior art date
Application number
DK159689A
Other languages
Danish (da)
English (en)
Other versions
DK159689D0 (da
Inventor
Navin Manohar Geria
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of DK159689D0 publication Critical patent/DK159689D0/da
Publication of DK159689A publication Critical patent/DK159689A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DK159689A 1988-04-04 1989-04-03 Medikeret hudplejepraeparat, dets fremstilling og anvendelse DK159689A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/176,898 US4992478A (en) 1988-04-04 1988-04-04 Antiinflammatory skin moisturizing composition and method of preparing same

Publications (2)

Publication Number Publication Date
DK159689D0 DK159689D0 (da) 1989-04-03
DK159689A true DK159689A (da) 1989-10-05

Family

ID=22646344

Family Applications (1)

Application Number Title Priority Date Filing Date
DK159689A DK159689A (da) 1988-04-04 1989-04-03 Medikeret hudplejepraeparat, dets fremstilling og anvendelse

Country Status (13)

Country Link
US (1) US4992478A (fr)
EP (1) EP0336902A3 (fr)
JP (1) JPH0215022A (fr)
KR (1) KR890015730A (fr)
AU (1) AU615042B2 (fr)
DK (1) DK159689A (fr)
FI (1) FI891593A (fr)
MX (1) MX166589B (fr)
NO (1) NO891380L (fr)
NZ (1) NZ228564A (fr)
PH (1) PH25897A (fr)
PT (1) PT90197B (fr)
ZA (1) ZA892366B (fr)

Families Citing this family (426)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9127062D0 (en) * 1991-12-20 1992-02-19 Unilever Plc Lip treatment composition
WO1994013257A1 (fr) * 1992-12-16 1994-06-23 Creative Products Resource Associates, Ltd. Lotion occlusive ou semi-occlusive pour le traitement de maladies ou de desordres cutanes
JP3566739B2 (ja) * 1993-09-30 2004-09-15 三省製薬株式会社 皮膚外用剤の安定化方法
US7135584B2 (en) * 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
WO1996006620A2 (fr) * 1994-08-29 1996-03-07 Wake Forest University Analogues de lipides pour le traitement d'infections virales
US5614489A (en) * 1995-05-25 1997-03-25 Mohammadi; Fatemeh Method and composition for treating the skin
FR2736827B1 (fr) * 1995-07-21 1997-09-19 Boucher Christine Bernard Huile cosmetique extraite des plantes du genre calophyllum
FR2737118B1 (fr) * 1995-07-28 1997-09-05 Oreal Composition dermatologique ou pharmaceutique, procede de preparation et utilisation
US5932553A (en) * 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
US5723632A (en) 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
DE19720083A1 (de) * 1997-05-14 1998-11-19 Silvia Zender Arzneimittel
AU746126B2 (en) * 1997-09-08 2002-04-18 Georgetown University Substituted 2-pyrrolidinone activators of PKC
US6486214B1 (en) 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US6156745A (en) * 1997-12-29 2000-12-05 Research Corporation Technologies, Inc. 2β-substituted-6-alkylidene penicillanic acid derivatives as β-lactamase inhibitors
US6245808B1 (en) 1998-11-05 2001-06-12 Parker Hughes Institute Oxy-vanadium (IV) complexes having spermicidal activity
US6432941B1 (en) 1998-01-20 2002-08-13 Parker Hughes Institute Vanadium compounds for treating cancer
US6051603A (en) * 1998-01-20 2000-04-18 Wayne Hughes Institute Vanadium (IV) metallocene complexes having sperm motility inhibiting activity
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6025328A (en) 1998-02-20 2000-02-15 The Regents Of The University Of California Antitumor agents
DE19825856A1 (de) * 1998-06-10 1999-12-16 Labtec Gmbh Topische Arzneimittelzubereitung
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
US6800649B1 (en) 1998-06-30 2004-10-05 Parker Hughes Institute Method for inhibiting c-jun expression using JAK-3 inhibitors
AUPP583198A0 (en) * 1998-09-11 1998-10-01 Soltec Research Pty Ltd Mousse composition
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
JP3211027B2 (ja) * 1998-11-13 2001-09-25 丸石製薬株式会社 カプサイシン含有外用剤
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
SK12582001A3 (sk) 1999-03-09 2002-02-05 Pharmacia & Upjohn Company 4-Oxo-4,7-dihydro-tieno[2,3-b] pyridín-5-karboxamidy ako antivírusové prostriedky, spôsob ich prípravy, medziprodukty a farmaceutická kompozícia
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
US6407091B1 (en) * 1999-04-15 2002-06-18 Research Corporation Technologies, Inc. β-lactamase inhibiting compounds
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
WO2000069470A2 (fr) * 1999-05-17 2000-11-23 Aesgen, Inc. Assimilation cellulaire amelioree d'agents bioactifs
WO2000078793A2 (fr) 1999-06-22 2000-12-28 University Of Louisville Research Foundation, Inc. Agents antimicrobiens
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US6740650B2 (en) 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
AU1608801A (en) 1999-11-15 2001-05-30 Parker Hughes Institute Diamino platinum (ii) antitumor complexes
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
US6589992B2 (en) 1999-11-30 2003-07-08 Parker Hughes Institute Inhibiting collagen-induced platelet aggregation
IL133968A0 (en) * 2000-01-10 2001-04-30 Thixo Ltd Therapeutic oils and edible pastes containing the same
US6967023B1 (en) * 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
US6451811B2 (en) 2000-03-21 2002-09-17 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents
NZ521523A (en) 2000-03-21 2004-05-28 Upjohn Co 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents
WO2001081318A1 (fr) 2000-03-21 2001-11-01 Pharmacia & Upjohn Company 4-hydroxycinnoline-3-carboxyamides utilises comme agents antiviraux
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US6682892B2 (en) * 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
US6696441B1 (en) 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response
CA2424013A1 (fr) 2000-09-29 2002-04-04 Regents Of The University Of Minnesota Triterpenes ayant une activite fongicide dirigee contre les levures
US6951847B2 (en) * 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
AU2001294959A1 (en) 2000-09-29 2002-04-08 Robert M. Carlson Triterpenes having antibacterial activity
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
US6878388B1 (en) 2000-11-15 2005-04-12 Parker Hughes Institute Vanadium compounds for treating proliferative cell disorders
US6642221B1 (en) 2000-11-15 2003-11-04 Parker Hughes Institute Vanadium compounds as anti-proliferative agents
US6958359B1 (en) 2000-11-15 2005-10-25 Parker Hughes Institute Vanadium compounds as anti-angiogenic agents
AU2002249885A1 (en) 2000-11-17 2002-08-12 Adolor Corporation Delta agonist analgesics
US7261901B2 (en) * 2001-01-31 2007-08-28 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
US7250172B2 (en) * 2001-01-31 2007-07-31 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
US7232829B2 (en) * 2001-04-06 2007-06-19 Regents Of The University Of Minnesota Therapeutic compounds and methods
JP2004520175A (ja) * 2001-05-29 2004-07-08 コーニンクレッカ　フィリップス　エレクトロニクス　エヌ　ヴィ 金属−セラミック接合
US20030232794A1 (en) * 2001-06-26 2003-12-18 Cottam Howard B. Use of STAT-6 inhibitors as therapeutic agents
US7601846B2 (en) * 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
EP1430060B1 (fr) * 2001-07-24 2006-09-13 Southern Methodist University Foundation for Research 7-alkylidene-3-substitues-3-cephem-4-carboxylates utilises en tant qu'inhibiteurs de beta-lactamase
US20030171377A1 (en) * 2001-08-29 2003-09-11 Bigge Christopher Franklin Antidiabetic agents
EP1423976A1 (fr) * 2001-08-31 2004-06-02 Thomson Licensing S.A. Compteur de sequences destine a un flux audio continu
US20040116350A1 (en) * 2001-09-17 2004-06-17 Paul Wentworth Jr Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US20040157280A1 (en) * 2001-09-17 2004-08-12 Paul Wentworth Antibody mediated ozone generation
US20050129680A1 (en) * 2001-09-17 2005-06-16 Paul Wentworth Antimicrobial activity of antibodies
EP1434782A2 (fr) * 2001-10-01 2004-07-07 University of Virginia Patent Foundation Analogues de 2-propynyle adenosine presentant une activite agoniste de a2a et compositions en contenant
WO2003031587A2 (fr) * 2001-10-09 2003-04-17 The Regents Of The University Of California Utilisation d'inhibiteurs de stat-6 comme agents therapeutiques
JP4628675B2 (ja) 2001-11-14 2011-02-09 ラトガーズ，ザ ステイト ユニバーシティ 可溶化トポイソメラーゼ毒
ATE424722T1 (de) * 2001-11-23 2009-03-15 Univ Rutgers Verbesserte synthese von polyanhydriden
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
AU2003205332A1 (en) * 2002-01-25 2003-09-02 Philip S. Portoghese Selective analgesic agents
JP2005525399A (ja) * 2002-04-04 2005-08-25 アラムクス エルエルシー セリンおよびメタロ−β−ラクタマーゼの阻害剤
AUPS158502A0 (en) * 2002-04-08 2002-05-16 Dermcare-Vet Pty Ltd Allergic dermatitis composition and method of treatment
WO2003086408A1 (fr) * 2002-04-10 2003-10-23 University Of Virginia Patent Foundation Utilisation d'agonistes du recepteur d'adenosine a2a dans le traitement de maladies inflammatoires
US20040156799A1 (en) * 2002-06-04 2004-08-12 Zigang Dong Cancer treatment method and compositions
UA79293C2 (en) * 2002-07-03 2007-06-11 Univ Wayne State 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents
JP4664071B2 (ja) * 2002-08-01 2011-04-06 エーザイ コーポレーション オブ ノース アメリカ グルタミンによるガンの改良治療
AU2003265406A1 (en) * 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted topoisomerase agents
US7438918B2 (en) * 2002-08-30 2008-10-21 University Of Iowa Research Foundation Lipid A deficient mutants of Neisseria meningitidis
BR0314219A (pt) * 2002-09-11 2005-07-19 Warner Lambert Co Inibidores do fator xa e outras serina proteases envolvidas na cascata da coagulação
EP2447278B1 (fr) 2002-10-10 2015-04-08 Cornell Research Foundation, Inc. Nouvelles protéines immunogènes de Leptospira
US20060183106A1 (en) * 2002-10-18 2006-08-17 Adam Siddiqui-Jain Processes for identifying quadruplex-targeted antiviral molecules
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20070292359A1 (en) * 2002-10-25 2007-12-20 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20070292355A1 (en) * 2002-10-25 2007-12-20 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US9265725B2 (en) * 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US20080317679A1 (en) * 2002-10-25 2008-12-25 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US20050186142A1 (en) * 2002-10-25 2005-08-25 Foamix Ltd. Kit and composition of imidazole with enhanced bioavailability
US7544674B2 (en) 2002-10-25 2009-06-09 Galderma S.A. Topical skin care composition
US8486376B2 (en) * 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7700076B2 (en) * 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) * 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20060193789A1 (en) * 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
US8119109B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20050205086A1 (en) * 2002-10-25 2005-09-22 Foamix Ltd. Retinoid immunomodulating kit and composition and uses thereof
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
KR101108439B1 (ko) * 2002-10-25 2012-01-31 포믹스 리미티드 화장료 및 약제용 거품제
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
EP1558647B1 (fr) 2002-11-08 2015-06-10 Ablynx N.V. Anticorps a domaine unique diriges contre le facteur de necrose tumorale alpha et leurs utilisations
US20060228355A1 (en) 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
CA2505316C (fr) 2002-11-08 2014-08-05 Ablynx N.V. Anticorps a domaine unique diriges contre le facteur de necrose tumorale alpha et leurs utilisations
BR0315628A (pt) * 2002-11-14 2005-08-23 Novartis Ag Geração de ozÈnio mediada por anticorpo ou neutrófilo
US7297340B2 (en) * 2003-01-07 2007-11-20 University Of Iowa Research Foundation Vaccine and method for preventing biofilm formation
CA2512545C (fr) 2003-01-10 2015-06-30 Karen Silence Recombinant vhh d'anticorps a domaine unique provenant de camelides cpntre le facteur von willebran (vwf)
US20050079512A1 (en) * 2003-02-26 2005-04-14 Emerson Beverly M. Methods of modulating gene expression
US7163948B2 (en) * 2003-04-07 2007-01-16 Cylene Pharmaceuticals, Inc. Heterocyclic substituted 1,4-dihydri-4ox9-1,8-naphthyridine analogs
US7354916B2 (en) * 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
CA2521810A1 (fr) * 2003-04-07 2004-10-28 Jeffrey P. Whitten Analogues de quinobenzoxazine substitues
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
SI1653943T1 (sl) 2003-06-25 2008-08-31 Burnham Inst Derivati katehola za zdravljenje raka
WO2005003140A1 (fr) * 2003-07-02 2005-01-13 Pharmacia & Upjohn Company Llc 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides utilises comme agents antiviraux
US20070140999A1 (en) * 2003-07-18 2007-06-21 Hill Dermaceuticals, Inc. Topical skin care composition containing refined peanut oil
WO2005009406A1 (fr) * 2003-07-18 2005-02-03 Hill Dermaceuticals, Inc. Composition topique de soins de la peau contenant de l'huile de cacahuetes raffinee
US8486374B2 (en) * 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
ES2440467T3 (es) 2003-08-25 2014-01-29 Dogwood Pharmaceuticals, Inc. 8-heteroaril xantinas substituidas
WO2005020928A2 (fr) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents et procedes permettant d'ameliorer la formation osseuse a l'aide d'oxysterols combines a des proteines morphogeniques osseuses
US20060099173A1 (en) * 2003-10-24 2006-05-11 Nancy Puglia Topical skin care composition
ATE502298T1 (de) * 2003-12-19 2011-04-15 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
ZA200507017B (en) * 2004-02-04 2007-03-28 Foamix Ltd Cosmetic and pharmaceutical foam with solid matter
WO2005077377A1 (fr) * 2004-02-06 2005-08-25 Regents Of The University Of Minnesota Compositions comprenant un triterpene et un excipient
CN1956966B (zh) 2004-02-19 2012-04-18 雷克斯安公司 喹唑啉衍生物及其治疗用途
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
WO2005099693A2 (fr) * 2004-02-24 2005-10-27 The Regents Of The University Of California Methodes et substances permettant d'evaluer des therapies du cancer de la prostate, et composes s'y rapportant
LT2574341T (lt) 2004-03-29 2017-09-11 University Of South Florida Navikų ir vėžio efektyvus gydymas triciribino fosfatu
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
SG155182A1 (en) 2004-08-02 2009-09-30 Univ Virginia 2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity
WO2006026380A2 (fr) * 2004-08-25 2006-03-09 University Of Iowa Research Foundation Inhibiteurs de la geranylgeranyl pyrophosphate synthase
US7718680B2 (en) * 2004-09-23 2010-05-18 Burnham Institute For Medical Research Inhibition of lethal factor protease activity from anthrax toxin
CA2583017A1 (fr) * 2004-10-13 2006-04-20 Ablynx N.V. Nanocorps contre la proteine beta-amyloide et polypeptides les renfermant pour le traitement de maladies degeneratives neurales, telles que la maladie d'alzheimer
US8697674B2 (en) 2004-12-29 2014-04-15 Naturon, Inc. Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
EP1845778A2 (fr) * 2005-01-10 2007-10-24 University Of Virginia Patent Foundation Synthese d'inhibiteurs de p90rsk
WO2007039825A2 (fr) * 2005-05-09 2007-04-12 Foamix Ltd. Compositions expansibles saccharidiques
CN101222922B (zh) 2005-05-13 2012-04-18 加利福尼亚大学董事会 二芳基乙内酰脲化合物
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
LT2949668T (lt) 2005-05-18 2019-11-11 Ablynx Nv Pagerinti nanokūnai tm prieš navikų nekrozės faktorių alfa
EP2007814A2 (fr) 2005-05-20 2008-12-31 Ablynx N.V. "nanobodies " (nanocorps) perfectionnes pour traiter des troubles medies par une agregation
CA2611147C (fr) 2005-06-01 2013-04-09 Stiefel Research Australia Pty Ltd. Formulation d'emulsion topique
US20080152596A1 (en) * 2005-07-19 2008-06-26 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
ATE527998T1 (de) * 2005-08-03 2011-10-15 Univ California Illudin-analoga als krebsmittel
EP1931352B1 (fr) 2005-08-22 2016-04-13 The Regents of The University of California Agonistes tlr
US20070098660A1 (en) * 2005-10-27 2007-05-03 Jim Taneri Methods and compositions for epilation
US20070098667A1 (en) * 2005-10-27 2007-05-03 Jim Taneri Methods and compositions for epilation
US20090291437A1 (en) * 2005-11-02 2009-11-26 O'brien Sean Methods for targeting quadruplex sequences
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
EP1993558B1 (fr) 2006-02-27 2014-07-30 The Regents of The University of California Composés oxystérols et hedgehog voie
JP2009530392A (ja) * 2006-03-22 2009-08-27 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア タンパク質プレニルトランスフェラーゼの阻害剤
EP2656841B1 (fr) * 2006-03-27 2016-08-10 The Regents of The University of California Modulateur de récepteur androgène pour le traitement du cancer de la prostate et de maladies associées au récepteur androgène
CN102755318B (zh) 2006-03-29 2014-09-10 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物
US8093235B2 (en) 2006-04-25 2012-01-10 Rutgers, The State University Of New Jersey Macrocyclic compounds which stabilize G-Quadruplex DNA and RNA
WO2007139778A2 (fr) * 2006-05-22 2007-12-06 University Of Virginia Patent Foundation Influence des substituants de rhamnose sur la puissance de sl0101, un inhibiteur de la ser/thr kinase, rsk
US20110112086A1 (en) * 2006-06-08 2011-05-12 Cylene Pharmaceuticals, Inc. Pyridinone analogs
US20100305136A1 (en) * 2006-06-08 2010-12-02 Johnny Yasuo Nagasawa Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US20080166303A1 (en) * 2006-09-08 2008-07-10 Dov Tamarkin Colored or colorable foamable composition and foam
US20080260655A1 (en) * 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
EP2073794A2 (fr) * 2006-11-14 2009-07-01 Foamix Ltd. Compositions d'émulsion pharmaceutiques moussantes, stables et non alcooliques, contenant un émollient onctueux et leurs utilisations
US8034829B2 (en) 2006-11-17 2011-10-11 Rexahn Pharmaceuticals, Inc. 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives and therapeutic use thereof
EP2086962A1 (fr) * 2006-11-29 2009-08-12 Pfizer Products Inc. 1- [ ( 4 -chlorophényl) amide 5-{[2-fluoro-4- (2-oxo-2h-pyridin-1-yl) -phényl]amide) d'acide (r) -5-méthyl-4, 5-dihydro- pyrazole-1, 5-dicarboxylique servant d'inhibiteur du facteur xa
EP2102244A2 (fr) 2006-12-19 2009-09-23 Ablynx N.V. Séquences d'acides aminés dirigées contre une métalloprotéinase de la famille adam et polypeptides les comprenant à des fins de traitement de maladies et troubles liés à adam
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2111385B1 (fr) 2007-02-06 2014-11-12 University Of Louisville Research Foundation, Inc. Alcynes substitués comme agents antitumoraux
PL2510946T3 (pl) 2007-02-07 2015-12-31 Univ California Koniugaty syntetycznych agonistów tlr i ich zastosowania
WO2008103818A1 (fr) * 2007-02-21 2008-08-28 University Of Louisville Research Foundation Compositions thérapeutiques à base de cotinine
US8569449B2 (en) 2007-05-08 2013-10-29 University Of Louisville Research Foundation, Inc. Synthetic peptides and peptide mimetics
CA2695330C (fr) * 2007-07-12 2017-06-13 University Of South Florida Inhibiteurs de akt/pkb a activite antitumorale
MX2010001303A (es) 2007-08-02 2010-09-07 Univ Rutgers Compuestos terapeuticos.
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
NZ584892A (en) * 2007-10-05 2012-06-29 Cylene Pharmaceuticals Inc Quinolone analogs and methods related thereto
WO2009052443A1 (fr) 2007-10-19 2009-04-23 Burnham Institute For Medical Research Inhibiteurs à base de naphtalène de protéines anti-apoptotiques
WO2009055677A1 (fr) * 2007-10-24 2009-04-30 University Of South Florida Disulfures s-hétérosubstitués antibactériens
JP5535925B2 (ja) 2007-10-26 2014-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物
US20090130029A1 (en) * 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
CA2707663C (fr) 2007-12-03 2017-05-30 The Regents Of The University Of California Oxysterols pour l'activation du signal hedgehog, de l'osteoinduction, de l'anti-adipogenese et du signal wnt
WO2010041141A2 (fr) 2008-10-07 2010-04-15 Foamix Ltd. Support expansible à base d’huile et préparations
WO2009072007A2 (fr) 2007-12-07 2009-06-11 Foamix Ltd. Porteurs, formulations, procédés pour formuler des agents actifs instables pour application externe et utilisations associées
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
AU2009205314A1 (en) * 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
WO2009108716A2 (fr) 2008-02-27 2009-09-03 University Of Louisville Research Foundation Peptides synthétiques
WO2009114539A2 (fr) * 2008-03-10 2009-09-17 University Of Louisville Research Foundation Traitements neuroprotecteurs à base de peptide de liaison de l'intégrine et de l'angiopoïétine-1
US20110046101A1 (en) * 2008-03-17 2011-02-24 Dmitrienko Gary I Bate-lactamase inhibitors
WO2009146112A1 (fr) * 2008-04-02 2009-12-03 University Of Virginia Patent Foundation Compositions et procédés pour inhiber la sphingosine kinase
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
RU2527561C2 (ru) * 2008-04-16 2014-09-10 Говард Юнивесити Ингибиторы протеинфосфатазы-1 и их применение
RU2010151725A (ru) 2008-05-16 2012-06-27 Аблинкс Нв (Be) Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их
US9872867B2 (en) * 2008-06-06 2018-01-23 Tanya Kuritz Methods and compositions for modulation of innate immunity
US20090324506A1 (en) * 2008-06-30 2009-12-31 Jeffery Richard Seidling Sprayable skin protectant formulation and method of use
US8673910B2 (en) * 2008-06-30 2014-03-18 H. Lee Moffitt Cancer Center And Research Institute Proteasome inhibitors for selectively inducing apoptosis in cancer cells
US7947717B2 (en) * 2008-07-18 2011-05-24 Burnham Institute For Medical Research Inhibitors of lethal factor protease
US9174969B2 (en) * 2008-07-21 2015-11-03 University Of South Florida Indoline scaffold SHP-2 inhibitors and cancer treatment method
US9125821B2 (en) 2008-07-28 2015-09-08 The Regents Of The University Of California Nanodrug targeting protein geranylgeranylation
WO2010014054A1 (fr) * 2008-07-28 2010-02-04 The Regents Of The University Of California Inhibiteurs de prényltransférases de protéine
CN102215860A (zh) 2008-08-05 2011-10-12 南佛罗里达大学 治疗认知损害的方法
US9132168B2 (en) 2008-08-05 2015-09-15 University Of South Florida Methods of treating cognitive impairment
AU2009279400A1 (en) * 2008-08-08 2010-02-11 University Of Florida Research Foundation, Inc. Lipid compounds for supression of tumorigenesis
US9480691B1 (en) * 2009-01-20 2016-11-01 Hill Dermaceuticals, Inc. Topical liquid containing refined peanut oil for treating skin proliferation or inflammation disorders
TW201038578A (en) 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
CN102438619A (zh) 2009-03-20 2012-05-02 衣阿华大学研究基金会 作为抗结核剂的异戊二烯化双膦酸盐
NZ595461A (en) 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
US8487131B2 (en) 2009-04-15 2013-07-16 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
AU2010236416A1 (en) 2009-04-15 2011-11-03 Sanford-Burnham Medical Research Institute Naphthalene-based inhibitors of anti-apoptotic proteins
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
EP2430016B1 (fr) 2009-05-13 2020-04-01 University Of Virginia Patent Foundation Inhibiteurs de leucémie inv(16)
CN102666563A (zh) 2009-06-30 2012-09-12 里克特格德翁公司 作为a2a受体激动剂的烷氧基羰基氨基炔基腺苷化合物及其衍生物
WO2011005871A1 (fr) 2009-07-07 2011-01-13 Pgxhealth, Llc 8-[6-carbonylamino-3-pyridyle] xanthines substituées en tant qu’antagonistes de l’adénosine a2b
CA2769625C (fr) 2009-07-29 2017-04-11 Foamix Ltd. Compositions hydro-alcooliques moussantes non tensioactives, mousses legeres, et leurs utilisations
WO2011013008A2 (fr) 2009-07-29 2011-02-03 Foamix Ltd. Compositions hydro-alcooliques moussantes à base d'agents non tensioactifs non polymères, mousses légères, et leurs utilisations
WO2011014817A1 (fr) 2009-07-31 2011-02-03 Biocryst Pharmaceuticals, Inc. Utilisation de dérivés de pyrrolo.[1, 2-b] pyridazine en tant qu’inhibiteurs de la janus kinase
US9040673B2 (en) 2009-08-14 2015-05-26 University Of Virginia Patent Foundation Synthesis and identification of novel RSK-specific inhibitors
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
US8642088B2 (en) 2009-09-04 2014-02-04 Wisconsin Alumni Research Foundation Tannin-chitosan composites
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
EA201270347A1 (ru) * 2009-10-08 2012-11-30 Санфорд-Бернхам Медикал Ресерч Инститъют Производные апогоссиполона в качестве противоопухолевых агентов
US8796300B2 (en) 2009-11-05 2014-08-05 Rutgers, The State University Of New Jersey Therapeutic compounds
JP2013515740A (ja) 2009-12-23 2013-05-09 バイオクライスト ファーマシューティカルズ， インコーポレイテッド Ｊａｎｕｓキナーゼインヒビターとしての複素環式化合物
WO2011079305A1 (fr) 2009-12-23 2011-06-30 Wayne State University Composés thérapeutiques
SI3124481T1 (en) 2010-02-16 2018-06-29 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and their use
CA2828114A1 (fr) 2010-02-26 2011-09-01 Gary Igor DMITRIENKO Derives de la cephalosporine utiles comme inhibiteurs de la .beta.-lactamase et leurs compositions et procedes d'utilisation
EP2552885A1 (fr) 2010-04-02 2013-02-06 TSRL, Inc. Inhibiteurs de la neuraminidase
US9221808B2 (en) 2010-04-16 2015-12-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use
WO2011133696A2 (fr) 2010-04-20 2011-10-27 Regents Of The University Of Minnesota Méthodes de lutte contre l'athérosclérose
MX2012013824A (es) 2010-05-28 2013-03-12 Biocryst Pharm Inc Compuestos heterociclicos como inhibidores de cinasa janus.
WO2012027494A1 (fr) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Réactifs bispécifiques de ciblage
WO2012027495A1 (fr) 2010-08-27 2012-03-01 University Of The Pacific Analogues de pipérazinylpyrimidine en tant qu'inhibiteurs de protéine kinase
DK2913044T3 (en) 2010-09-20 2018-07-30 Oreal AQUEY COSMETIC COMPOSITION INCLUDING ALKYL CELLULOSE
CN107375019A (zh) 2010-09-20 2017-11-24 欧莱雅 包含烷基纤维素的含水美容组合物
US9364505B2 (en) 2010-10-25 2016-06-14 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
PL2672823T3 (pl) 2011-02-07 2017-02-28 Biogen Ma Inc. Czynniki modulujące działanie receptora s1p
CA2865487A1 (fr) 2011-03-07 2012-09-13 Paula J. Bates Marqueur predictif de l'efficacite therapeutique de l'inhibiteur dnmt1, et procedes d'utilisation dudit marqueur
US9616064B2 (en) 2011-03-30 2017-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rho kinase inhibitors and methods of use
CN103826657A (zh) 2011-04-04 2014-05-28 衣阿华大学研究基金会 改进疫苗免疫原性的方法
EP2694079B1 (fr) 2011-04-06 2018-01-17 Rutgers, The State University of New Jersey Polymères et procédés pour le traitement de la douleur
US20120270860A1 (en) 2011-04-19 2012-10-25 Gihyun Yoon Methods for treating or preventing alcohol-related disorders or craving-related disorders
WO2012145678A1 (fr) 2011-04-20 2012-10-26 Regents Of The University Of Minnesota Composés parthénolides anticancéreux et anti-inflammatoire
US9415112B2 (en) 2011-06-20 2016-08-16 Rutgers, The State University Of New Jersey Bipartite inhibitors of bacterial RNA polymerase
EP2729483A1 (fr) 2011-07-08 2014-05-14 Regents Of The University Of Minnesota Analogues du glutathion et leurs utilisations
AU2012287103B2 (en) 2011-07-22 2017-03-30 University Of Louisville Research Foundation, Inc. Anti-biofilm compounds
EP3791724A1 (fr) 2011-07-29 2021-03-17 Medivation Prostate Therapeutics LLC Traitement du cancer du sein
WO2013028866A1 (fr) 2011-08-24 2013-02-28 Regents Of The University Of Minnesota Composés et méthodes thérapeutiques
US9034336B2 (en) 2011-08-30 2015-05-19 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
US9598441B2 (en) 2011-08-30 2017-03-21 Wayne State University Therapeutic compounds and methods
WO2013036931A1 (fr) 2011-09-08 2013-03-14 Western University Of Health Sciences Liposomes ciblés en thérapie cancéreuse
JP2014527083A (ja) 2011-09-15 2014-10-09 アリゾナ ボード オブ リージェンツ， ア ボディー コーポレイト オブ ザ ステート オブ アリゾナ， アクティング フォー アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティー 治療用化合物
US9828326B2 (en) * 2011-12-27 2017-11-28 Northeast Ohio Medical University Amooranin compounds and analogs thereof and related methods of use
FR2985176B1 (fr) 2012-01-02 2015-05-29 Oreal Composition cosmetique liquide aqueuse comprenant de l'alkylcellulose, des huiles non volatiles et au moins un tensioactif
WO2013103969A1 (fr) 2012-01-05 2013-07-11 Rutgers, The State University Of New Jersey Agents antibactériens : dérivés du phloroglucinol
CA2862999A1 (fr) 2012-01-11 2013-07-18 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Fragments d'anticorps bispecifiques pour proteines associees a une maladie neurologique, et procedes d'utilisation
US8947424B2 (en) 2012-01-17 2015-02-03 Eastman Kodak Company Spectral stereoscopic projection system
EP3269372B1 (fr) 2012-01-19 2019-06-12 Hybrid Medical, LLC Préparations thérapeutiques topiques
EP2804852A2 (fr) 2012-01-20 2014-11-26 Regents Of The University Of Minnesota Composés thérapeutiques
CA2863427C (fr) 2012-02-01 2022-07-12 The Governors Of The University Of Alberta Utilisation de pdgfr-alpha en tant que marqueur de diagnostic pour le cancer de la thyroide papillaire
US20130195752A1 (en) 2012-02-01 2013-08-01 Regents Of The University Of Minnesota Functionalized nanoparticles and methods of use thereof
WO2013119564A1 (fr) 2012-02-06 2013-08-15 Rutgers, The State University Of New Jersey Agents antibactériens : combinaison d'une rifamycine et d'un inhibiteur de région de transition
US9688668B2 (en) 2012-02-08 2017-06-27 University Of Virginia Patent Foundation Long chain base sphingosine kinase inhibitors
WO2013142812A1 (fr) 2012-03-22 2013-09-26 Rutgers, The State University Of New Jersey Agents antibactériens : dérivés de myxopyronine à chaîne latérale fluorée
EP2831063B1 (fr) 2012-03-26 2017-10-04 University of Iowa Research Foundation Analogues de schweinfurthines
WO2013158197A1 (fr) 2012-04-16 2013-10-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dérivés de marinopyrrole comme agents anticancéreux
US9272016B2 (en) 2012-04-20 2016-03-01 University Of Iowa Research Foundation Methods to enhance RNAi oligonucleotide delivery to respiratory epithelial cells
US9717742B2 (en) 2012-05-07 2017-08-01 The Regents Of The University Of California Oxysterol analogue OXY133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
EP2861570B1 (fr) 2012-06-19 2018-07-18 Rutgers, The State University of New Jersey Agents antibactériens : dérivés aryliques de la myxopyronine
ES2784223T3 (es) 2012-06-20 2020-09-23 Univ Virginia Patent Foundation Composiciones y procedimientos para regular la homeostasis de glucosa y la acción de insulina
US9669115B2 (en) 2012-06-29 2017-06-06 University Of Iowa Research Foundation Co-crystals and salts of contrast agents and imaging
AU2013286683B2 (en) 2012-07-05 2017-07-13 University Of Iowa Research Foundation Therapeutic bisphosphonates
AU2013292529A1 (en) 2012-07-18 2015-02-12 Marvin J. Miller 5,5-heteroaromatic anti-infective compounds
WO2014018671A1 (fr) 2012-07-24 2014-01-30 Regents Of The University Of Minnesota Composés thérapeutiques pour le traitement du cancer
NZ703852A (en) 2012-07-27 2018-03-23 Biogen Ma Inc Atx modulating agents
CA2880040A1 (fr) 2012-08-01 2014-02-06 Lewis And Clark Pharmaceuticals, Inc. Utilisation de n-alkyl-2-(disubstitue)alkynyladenosine-5-uronamides comme agonistes du recepteur a2a
CN104981461B (zh) 2012-08-03 2017-09-29 伊利诺伊大学评议会 激活酶的化合物及组合物
ES2691793T3 (es) 2012-08-06 2018-11-28 Biogen Ma Inc. Derivados de naftaleno 1,5,6-sustituidos como moduladores de receptor de 1-fosfato de esfingosina (S1P) y/o autotaxina (ATX) para tratar trastornos inflamatorios y autoinmunitarios
WO2014025708A1 (fr) 2012-08-06 2014-02-13 Biogen Idec Ma Inc. Composés étant des agents de modulation de s1p et/ou des agents de modulation d'atx
ES2877570T3 (es) 2012-08-22 2021-11-17 Univ Cornell Métodos para inhibir fascina
US9737493B2 (en) 2012-09-07 2017-08-22 University Of Louisville Research Foundation, Inc. Compositions and methods for modulating DNMT1 inhibitor activity
US9573938B2 (en) 2012-09-11 2017-02-21 Rutgers, The State University Of New Jersey Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones
SI3305285T1 (sl) 2012-09-26 2021-03-31 Aragon Pharmaceuticals, Inc. Anti-androgeni za zdravljenje proti kastraciji odpornega ne-metastatskega raka
JP2016501832A (ja) 2012-10-10 2016-01-21 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 多機能ラジカル消光剤
WO2014059350A1 (fr) 2012-10-12 2014-04-17 Regents Of The University Of Minnesota Dérivés de 1,1 '-alkylène-bis-uracile à chaîne ouverte ou fusionnés, utiles dans la protection uv de la peau
WO2014066840A1 (fr) 2012-10-26 2014-05-01 Regents Of The University Of Minnesota Inhibiteurs d'aurora kinase
WO2014070774A1 (fr) 2012-10-29 2014-05-08 Southern Methodist University Procédés de génération de composés de carbapénem résistants à la bêta-lactamase
WO2014074926A1 (fr) 2012-11-09 2014-05-15 Rutgers, The State University Of New Jersey Hydroxyquinolones thérapeutiques
WO2014078778A2 (fr) 2012-11-16 2014-05-22 Biocryst Pharmaceuticals, Inc. Nucléosides antiviraux contenant de l'azasucre
CN105189492A (zh) 2012-11-19 2015-12-23 萨克·W·金 麦角灵衍生物作为多巴胺受体调节剂
US9771326B2 (en) 2012-11-20 2017-09-26 Biogen Ma Inc. S1P and/or ATX modulating agents
WO2014081752A1 (fr) 2012-11-20 2014-05-30 Biogen Idec Ma Inc. Agents modulant s1p et/ou atx
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
WO2014116634A1 (fr) 2013-01-22 2014-07-31 Chongqing Zein Pharmaceutical Co., Ltd. Dérivés marinopyrroles symétriques en tant qu'agents présentant un potentiel antibiotique
CA2899322A1 (fr) 2013-01-29 2014-08-07 Biogen Ma Inc. Agents modulateurs de s1p
US9981043B2 (en) 2013-02-08 2018-05-29 Regents Of The University Of Minnesota Analgesic conjugates
US9776975B2 (en) 2013-03-05 2017-10-03 University Of Notre Dame Du Lac Quinazolinone antibiotics
EP2970334B1 (fr) 2013-03-15 2018-05-23 Biogen MA Inc. Composés macrocycliques comme inhibiteurs d'irak4 pour le traitement de maladies inflammatoires
US9387250B2 (en) 2013-03-15 2016-07-12 Rutgers, The State University Of New Jersey Therapeutic compositions for bone repair
EP2970302A1 (fr) 2013-03-15 2016-01-20 Biogen MA Inc. Modulateurs de s1p et/ou de l'atx
JP2016519672A (ja) 2013-03-15 2016-07-07 ジェネンテック， インコーポレイテッド ブロモドメイン含有タンパク質ｂｒｄ７およびｂｒｄ９の阻害によるｔｈ２媒介性疾患の治療
US9683009B2 (en) 2013-05-02 2017-06-20 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
US9862672B2 (en) 2013-05-29 2018-01-09 Rutgers, The State University Of New Jersey Antioxidant-based poly(anhydride-esters)
US9987211B2 (en) 2013-07-03 2018-06-05 Regents Of The University Of Minnesota Sunless tanning compounds and compositions
US9850216B2 (en) 2013-08-06 2017-12-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors of ACK1/TNK2 tyrosine kinase
US10624943B2 (en) 2013-11-11 2020-04-21 Kuality Herbceutics, LLC Kava derived therapeutic compounds and methods of use thereof
US9339482B2 (en) 2013-11-22 2016-05-17 Regents Of The University Of Minnesota Methods to treat dysregulated blood glucose disorders
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
US9919998B2 (en) 2014-02-06 2018-03-20 Rutgers, The State University Of New Jersey Antibacterial agents: Nα-aroyl-N-aryl-phenylalaninamides
WO2015127125A1 (fr) 2014-02-20 2015-08-27 Cornell University Composés et procédés d'inhibition de la fascine
US10189874B2 (en) 2014-02-26 2019-01-29 Arizona Board Of Regents On Behalf Of Arizona State University DNA gridiron compositions and methods
US10272055B2 (en) 2014-03-06 2019-04-30 Regents Of The University Of Minnesota Therapeutic compounds and methods
EP3828173B1 (fr) 2014-03-07 2022-08-31 BioCryst Pharmaceuticals, Inc. Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
US10197575B2 (en) 2014-03-31 2019-02-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stabilized peptoid-peptide hybrids and uses thereof
US10266603B2 (en) 2014-04-18 2019-04-23 The Governors Of The University Of Alberta Targeted therapy to restore radioactive iodine transport in thyroid cancer
US9556113B2 (en) 2014-04-29 2017-01-31 The South Dakota Board Of Regents Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment
AU2015252859B2 (en) 2014-05-02 2019-11-07 The Regents Of The University Of California Bone-selective osteogenic oxysterol bisphosphonate analogs
US9987299B2 (en) 2014-05-05 2018-06-05 University Of Iowa Research Foundation Methods of improving RNAi in well-differentiated airway epithelia
US10144732B2 (en) 2014-06-06 2018-12-04 Biogen Ma Inc. ATX modulating agents
US10138203B2 (en) 2014-06-16 2018-11-27 Rutgers, The State University Of New Jersey Antibacterial agents
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
KR102299276B1 (ko) * 2014-07-16 2021-09-09 (주)아모레퍼시픽 납떼기콩 오일을 포함하는 조성물
EP3265130B1 (fr) 2014-08-19 2024-05-22 Hsiri Therapeutics, LLC Sidéromycines antibactériennes
CA2964239C (fr) 2014-09-11 2022-12-13 University Of Iowa Research Foundation Thymol et carvacol destines a un usage medical
WO2016076929A1 (fr) 2014-11-13 2016-05-19 University Of Iowa Research Foundation Procédés pour générer des cellules épithéliales
CA2976937C (fr) 2015-02-17 2023-04-04 Arizona Board Of Regents On Behalf Of Arizona State University Composes therapeutiques
JP6807337B2 (ja) 2015-02-17 2021-01-06 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ ミトコンドリア治療剤としてのフェノチアジン類似体
WO2016172187A1 (fr) 2015-04-20 2016-10-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Méthodes et compositions associées à des inhibiteurs de kras
JP6959142B2 (ja) 2015-05-06 2021-11-02 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Ｍｃ１ｒを標的とする放射線療法用作用物質およびコンパニオンイメージング作用物質
US10584108B2 (en) 2015-05-07 2020-03-10 Kuality Herbceutics Llc Therapeutic compounds and methods of use thereof
CA2986423C (fr) 2015-05-18 2022-05-10 The Arizona Board Of Regents On Behalf Of The University Of Arizona Amelioration de la prevention du cancer par de nouvelles melanotrines
WO2016205397A2 (fr) 2015-06-15 2016-12-22 Klibanov Alexander L Administration spécifique de cible d'agents thérapeutiques
US10308663B2 (en) 2015-06-16 2019-06-04 University Of Virginia Patent Foundation Inhibitors of PTP4A3 for the treatment of cancer
WO2017011686A1 (fr) 2015-07-14 2017-01-19 University Of Iowa Research Foundation Promédicaments fluorescents
EP3328372A4 (fr) 2015-07-28 2019-03-20 University Of Iowa Research Foundation Compositions et méthodes de traitement du cancer
AU2016301212A1 (en) 2015-08-02 2018-03-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors of ACK1/TNK2 tyrosine kinase
WO2017027883A1 (fr) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomérisme pour une sélectivité accrue des inhibiteurs de kinase
CA2997545C (fr) 2015-09-04 2022-01-11 Janssen Pharmaceutica Nv Composes therapeutiques pour la douleur et synthese connexe
AU2016332847B2 (en) 2015-10-01 2023-08-10 Goleini Inc. Targeted expression of chloride channels and methods of use thereof
KR20180058815A (ko) 2015-10-01 2018-06-01 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
WO2017066428A1 (fr) 2015-10-13 2017-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Inhibiteurs de brd4-kinase à utiliser en tant qu'agents thérapeutiques anticancéreux
WO2017079335A1 (fr) 2015-11-03 2017-05-11 Regents Of The University Of Minnesota Inhibiteurs de cd200 et leurs méthodes d'utilisation
WO2017087235A1 (fr) 2015-11-20 2017-05-26 Senhwa Biosciences, Inc. Polythérapie comprenant des analogues de la quinolone tétracyclique pour le traitement du cancer
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
US9980951B2 (en) 2015-12-17 2018-05-29 University Of Iowa Research Foundation Image guided therapy for cancer
KR102108114B1 (ko) 2015-12-21 2020-05-11 로레알 알킬셀룰로오스, 불상용성 탄화수소 및 실리콘 오일을 포함하는 조성물 및 이의 이용 방법
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
TWI747873B (zh) 2016-02-01 2021-12-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
WO2017156527A1 (fr) 2016-03-11 2017-09-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibiteurs des kinases aurora et des janus kinases pour la prévention de la maladie du greffon contre l'hôte
MX2018011216A (es) 2016-03-16 2019-08-29 H Lee Moffitt Cancer Ct & Res Moléculas pequeñas contra cereblon para mejorar la función efectora de los linfocitos t.
US11529340B2 (en) 2016-03-22 2022-12-20 Regents Of The University Of Minnesota Combination for treating pain
WO2017165836A1 (fr) 2016-03-24 2017-09-28 Rutgers, The State University Of New Jersey Agents antibactériens
US11091498B2 (en) 2016-04-04 2021-08-17 Rutgers, The State University Of New Jersey Topoisomerase poisons
US10551384B2 (en) 2016-04-07 2020-02-04 Rutgers, The State University Of New Jersey MTOR kinase mutations and methods of use thereof
EP3445838B1 (fr) 2016-04-18 2023-05-10 Gene Pool Technologies, Inc. Isolement d'extraits de plantes
RU2018142711A (ru) 2016-05-04 2020-06-04 Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. Средство для целенаправленного воздействия на дельта-опиоидный рецептор для молекулярной визуализации и иммунотерапии рака
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
CN110337293A (zh) 2016-06-20 2019-10-15 新泽西鲁特格斯州立大学 治疗性化合物
WO2017223565A1 (fr) 2016-06-24 2017-12-28 University Of Iowa Research Foundation Compositions et procédés de traitement d'un mélanome
WO2018022802A1 (fr) 2016-07-26 2018-02-01 University Of Southern California Inhibition sélective de bromodomaine de bdf1 fongique
WO2018039077A1 (fr) 2016-08-25 2018-03-01 Arizona Board Of Regents On Behalf Of Arizona State University Composés thérapeutiques
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
MA46546A (fr) 2016-10-17 2021-05-05 Genentech Inc Composés thérapeutiques et leurs procédés d'utilisation
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
DK3532057T3 (da) 2016-10-31 2023-02-20 Biocryst Pharm Inc Prodrugs af kallikreininhibitorer
CN110234238B (zh) 2016-11-29 2023-03-28 爱荷华大学研究基金会 Nad前体用于改善母体健康和/或后代健康的用途
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
US10710957B2 (en) 2017-01-09 2020-07-14 University Of Central Florida Research Foundation, Inc. Motuporamine derivatives as antimicrobial agents and antibiotic enhancers against resistant gram-negative bacteria
WO2018136792A1 (fr) 2017-01-20 2018-07-26 The Regents Of The University Of California Inhibiteurs du domaine n-terminal du récepteur d'androgène
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US11090289B2 (en) 2017-01-24 2021-08-17 University Of Virginia Patent Foundation Compositions and methods for blocking sodium channels
US10294264B2 (en) 2017-04-21 2019-05-21 Warsaw Orthopedic, Inc. Oxysterol-therapeutic agent derivative for bone healing
EP3621617A1 (fr) 2017-05-12 2020-03-18 Innovus Pharmaceuticals, Inc. Méthodes thérapeutiques et compositions associees
US10434106B2 (en) 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
US11896591B2 (en) 2017-05-22 2024-02-13 University Of Virginia Patent Foundation Compositions and methods for preparing and using mitochondrial uncouplers
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
EP3641776B1 (fr) 2017-06-23 2023-10-18 San Diego State University Research Foundation Atropisomérisme pour une sélectivité améliorée des inhibiteurs de kinase
EP3676255A1 (fr) 2017-08-29 2020-07-08 Rutgers, The State University University Of New Jersey Indazoles thérapeutiques
EP4141117A1 (fr) 2017-08-30 2023-03-01 Arizona Board of Regents on behalf of Arizona State University Nanostructures arn et procédés de fabrication et d'utilisation de nanostructures arn
JP2020536891A (ja) 2017-10-06 2020-12-17 ブルー セラピューティクス，インコーポレイティド 急性又は慢性疼痛を治療する方法
JP7201694B2 (ja) 2017-10-16 2023-01-10 アラゴン ファーマシューティカルズ，インコーポレイテッド 非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤
JP7226830B2 (ja) 2017-11-30 2023-02-21 サイトジェル ファーマ リミテッド ライアビリティ カンパニー 新規の鎮痛薬製剤処方及びその使用
US11242533B2 (en) 2018-01-10 2022-02-08 Arizona Board Of Regents On Behalf Of Arizona State University RNA-nanostructured double robots and methods of use thereof
US10738093B2 (en) 2018-01-25 2020-08-11 The Hong Kong University Of Science And Technology Discovery of cationic nonribosomal peptides as Gram-negative antibiotics through global genome mining
EP3752143A4 (fr) 2018-02-13 2021-08-11 Rutgers, The State University of New Jersey Agents antibactériens : pyronines o-alkyl-deutérés
EP3752149A4 (fr) 2018-02-15 2022-03-02 Senhwa Biosciences, Inc. Analogues de quinolone, sels correspondants, compositions et procédé d'utilisation
WO2019168921A1 (fr) 2018-02-27 2019-09-06 University Of Virginia Patent Foundation Inhibiteur de liposomes/parp ciblés par plectine dans le traitement du cancer
WO2019173507A1 (fr) 2018-03-06 2019-09-12 Rutgers, The State University Of New Jersey Agents antibactériens : phloroglucinols arylalkylcarboxamido
TW202010742A (zh) 2018-04-06 2020-03-16 美商百歐克斯製藥公司 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑
KR20210003831A (ko) 2018-04-20 2021-01-12 버지니아 테크 인터렉추얼 프라퍼티스, 인크. 미토콘드리아 언커플러로서 유용한 아미노피라진 및 관련 화합물
US20210230601A1 (en) 2018-04-27 2021-07-29 Arizona Board Of Regents On Behalf Of Arizona State University Highly knotted molecular topologies from single-stranded nucleic acids
US10758594B2 (en) 2018-06-26 2020-09-01 Marine Essence Biosciences Corporation of USA Biomaterial devices and topical compositions for treatment of skin abnormalities
US10912822B2 (en) 2018-06-26 2021-02-09 Marine Essence Biosciences Corporation of USA Biomaterial devices and topical compositions for guided tissue regeneration
US11730726B2 (en) 2018-07-11 2023-08-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dimeric immuno-modulatory compounds against cereblon-based mechanisms
US10898460B1 (en) 2018-07-20 2021-01-26 University Of South Florida Leishmania inhibitors
US11987568B2 (en) 2018-08-03 2024-05-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Allosteric inhibitor of WEE1 kinase
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
JP6933394B2 (ja) * 2018-09-06 2021-09-08 マリン エッセンス バイオサイエンシズ コーポレーション オブ ユーエスエーＭａｒｉｎｅ Ｅｓｓｅｎｃｅ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ ｏｆ ＵＳＡ 組織再生誘導のためのバイオマテリアルデバイスおよび局所用組成物
EP3877439A4 (fr) 2018-11-07 2022-08-10 Regents of the University of Minnesota Compositions analgésiques et anti-accoutumance pour le traitement de la douleur chronique et de la dépendance aux opioïdes
CN113302206A (zh) 2018-11-26 2021-08-24 戴纳立制药公司 治疗脂质代谢失调的方法
CA3126156A1 (fr) 2019-01-14 2020-07-23 Regents Of The University Of Minnesota Ligands cd200ar pour immunotherapie anticancereuse
US10889601B2 (en) 2019-02-11 2021-01-12 University Of Iowa Research Foundation Separations using boron containing hydrocarbon sponges
WO2020225779A1 (fr) 2019-05-09 2020-11-12 Istituto Pasteur Italia - Fondazione Cenci Bolognetti Agonistes de rig-i pour le traitement du cancer et l'immunothérapie
WO2020263989A1 (fr) 2019-06-24 2020-12-30 University Of Iowa Research Foundation Inhibiteurs de jnk en tant qu'agents anticancéreux
US11840703B2 (en) 2019-07-01 2023-12-12 Matrexa LLC Recombinant versican isoforms and related compositions and methods
MX2022001608A (es) 2019-08-06 2022-03-11 Biocryst Pharm Inc Sintesis de un inhibidor de calicreina plasmatica a escala de proceso.
EP4136095A1 (fr) 2020-04-17 2023-02-22 Regents of the University of Minnesota Domaine de liaison au récepteur de spicule du sars-cov-2 et compositions et méthodes associées
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
WO2022155332A1 (fr) 2021-01-13 2022-07-21 Blue Therapeutics, Inc. Méthodes de traitement du syndrome du côlon irritable
EP4294805A1 (fr) 2021-02-22 2023-12-27 Regents of the University of Minnesota Immunomodulateurs et conjugués immunomodulateurs
AU2022270088A1 (en) 2021-05-04 2023-11-23 Regents Of The University Of Minnesota Contraceptive compounds and methods
WO2023081237A1 (fr) 2021-11-03 2023-05-11 Regents Of The University Of Minnesota Agonistes et antagonistes du récepteur de type toll et leurs utilisations
WO2023091689A1 (fr) 2021-11-19 2023-05-25 University Of Iowa Research Foundation Utilisation associée de radiothérapie dirigée par mcr1 et d'inhibition du point de contrôle immunitaire dans le traitement d'un mélanome
WO2024006977A1 (fr) 2022-07-01 2024-01-04 University Of Southern California Ligands bitopiques du récepteur opioïde delta analgésique
WO2024009283A1 (fr) 2022-07-07 2024-01-11 University Of Southern California Antagonistes at2 pour soulager la douleur non addictive
WO2024011214A1 (fr) 2022-07-08 2024-01-11 Actio Biosciences, Inc. Composés et méthodes thérapeutiques
WO2024102342A1 (fr) 2022-11-10 2024-05-16 University Of Iowa Research Foundation Combinaison d'un inhibiteur de la synthèse du glutathion tel que la buthionine sulfoximine et d'un inhibiteur de point de contrôle immunitaire, de préférence le pembrolizumab, pour traiter le cancer, de préférence un mélanome résistant aux médicaments
WO2024112932A1 (fr) 2022-11-23 2024-05-30 Regents Of The University Of Minnesota Immunomodulateurs et conjugués immunomodulateurs
WO2024124023A2 (fr) 2022-12-07 2024-06-13 Rutgers, The State University Of New Jersey Inhibiteurs d'enzyme anhydrase carbonique et leurs procédés d'utilisation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2041594A5 (fr) * 1969-04-30 1971-01-29 Expanscience
US4256664A (en) * 1973-03-12 1981-03-17 Colgate-Palmolive Company Substantive sunscreen agents
US4165385A (en) * 1973-05-29 1979-08-21 Dianis Creations, Inc. Water-in-oil emulsion for skin moisturizing
US4014995A (en) * 1973-09-19 1977-03-29 The Quaker Oats Company Cosmetics containing finely divided oat flour
US4380549A (en) * 1975-07-23 1983-04-19 Scott Eugene J Van Topical treatment of dry skin
GB2008943B (en) * 1977-11-26 1982-05-19 Beecham Group Ltd Cosmetic lotions
US4355028A (en) * 1978-04-04 1982-10-19 Westwood Pharmaceuticals, Inc. Composition for treating acne vulgaris
US4248861A (en) * 1979-02-21 1981-02-03 Schutt Steven R Skin treatment methods
US4233295A (en) * 1979-05-31 1980-11-11 E. R. Squibb & Sons, Inc. Corticosteroid formulations containing sebacate carrier
US4305936A (en) * 1980-10-09 1981-12-15 Dermik Laboratories Topical corticosteroid formulations
US4389418A (en) * 1981-02-25 1983-06-21 S. C. Johnson & Son, Inc. Skin care composition
LU83173A1 (fr) * 1981-02-27 1981-06-05 Oreal Nouvelles compositions cosmetiques pour le traitement des cheveux et de la peau contenant une poudre resultant de la pulverisation d'au moins une plante et un agent de cohesion
US4346086A (en) * 1981-06-09 1982-08-24 Beiersdorf Aktiengesellschaft Corticosteroid-containing cream
JPS588009A (ja) * 1981-07-08 1983-01-18 ギスト・ブロカデス・ナ−ムロ−ゼ・フエンノ−トチヤツプ 身体の局部療法のための組成物
US4368187A (en) * 1981-08-03 1983-01-11 Eli Lilly And Company Sensitive-skin care regime
US4368189A (en) * 1981-08-03 1983-01-11 Eli Lilly And Company Cosmetic moisturizer formulation
US4382960A (en) * 1981-08-03 1983-05-10 Eli Lilly And Company Cosmetic cleanser formulation
US4478853A (en) * 1982-05-17 1984-10-23 S. C. Johnson & Son, Inc. Skin conditioning composition
EP0103911A1 (fr) * 1982-06-30 1984-03-28 THE PROCTER & GAMBLE COMPANY Compositions pharmaceutiques topiques contenant un agent émollient
JPS59139315A (ja) * 1983-01-31 1984-08-10 Taisho Pharmaceut Co Ltd クリ−ム剤
JPS6038310A (ja) * 1983-08-11 1985-02-27 Kobayashi Kooc:Kk パ−ル剤組成物
US4563346A (en) * 1984-03-14 1986-01-07 Charles Of The Ritz Group Ltd. Topical delivery system and skin treatment compositions employing such system
DE3534743A1 (de) * 1985-09-28 1987-04-02 Beiersdorf Ag Hydrocortisondiester enthaltende o/w-creme

Also Published As

Publication number Publication date
MX166589B (es) 1993-01-20
FI891593A (fi) 1989-10-05
PT90197A (pt) 1989-11-10
NO891380L (no) 1989-10-05
FI891593A0 (fi) 1989-04-03
DK159689D0 (da) 1989-04-03
KR890015730A (ko) 1989-11-25
EP0336902A3 (fr) 1991-05-29
NO891380D0 (no) 1989-03-31
NZ228564A (en) 1991-06-25
PT90197B (pt) 1994-06-30
PH25897A (en) 1991-12-19
US4992478A (en) 1991-02-12
AU615042B2 (en) 1991-09-19
EP0336902A2 (fr) 1989-10-11
ZA892366B (en) 1989-12-27
JPH0215022A (ja) 1990-01-18
AU3232889A (en) 1989-10-05

Similar Documents

Publication Publication Date Title
DK159689A (da) Medikeret hudplejepraeparat, dets fremstilling og anvendelse
GB9326571D0 (en) Floor covering
SG94890G (en) Floor structure
GB8510677D0 (en) Floor construction
GB2152843B (en) Floor covering materials
GB9217232D0 (en) Floor covering
GB2183689B (en) Floor panel
GB2227035B (en) Floor panel
GB2191209B (en) Floor covering
AU5261790A (en) Floor covering element
GB8614848D0 (en) Covering
GB2203463B (en) Floor constructions
ATA390984A (de) Vorrichtung zum kontinuierlichen trennen von uebereinanderliegenden blattfoermigen gebilden
GB8707958D0 (en) Floor structures
GB9018890D0 (en) Floor covering structure
GB8610164D0 (en) Floor construction
CA62167S (en) Floor covering
AU6182886A (en) Furniture covering
GB8812984D0 (en) Improved floor covering
GB8506592D0 (en) Floor covering
GB2172622B (en) Floor construction
GB8712484D0 (en) Floor covering
GB8601267D0 (en) Floor covering
GB8612841D0 (en) Floor structures
GB8911692D0 (en) Floor covering

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment
PBP Patent lapsed